Johnson Matthey acquires Pharmorphix
Cambridge firm provides solid form services that are critical to successful drug discovery and development
Johnson Matthey has bought Sigma-Aldrich's Pharmorphix solid form research business adding material science capabilities to its expanding European API and clinical supply services.
No financial details about the transaction have been disclosed.
Pharmorphix, located at the Cambridge Science Park, UK, provides solid form services, including polymorph studies, salt selection, co-crystallisation, chiral separations and process scale up that are critical to successful drug discovery and development.
Johnson Matthey says this expertise also has valuable applications for process control, and can enable innovators or generics customers to find new forms for novel or existing pharmaceuticals.
'Pharmorphix serves an important niche area that complements our custom pharma solutions, API life cycle management offerings and existing US-based solid state science capabilities,' said John Fowler, Division Director at Johnson Matthey Fine Chemicals.
'The acquisition adds further differentiating technologies to our advanced catalysis and complex chemistry capabilities.'
The Pharmorphix facilities and staff will be integrated into Johnson Matthey’s expanding Cambridge presence.